BELLUS Health (TSX: BLU) announced today that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept study evaluating NC-503 (eprodisate disodium) as a treatment for Type 2 diabetes. The study did not meet its primary efficacy endpoint.
"While we are disappointed that the NC-503 indication for Type 2 Diabetes did not prove to be effective, our decision today enables us to preserve shareholder value and conserve our financial and human resources for projects that we believe have high potential for success," said Roberto Bellini, President and Chief Executive Officer of BELLUS Health.
Statins slightly up diabetes risk but cardiovascular benefits remain, finds study